| Case report: a p.C618S RET proto-oncogene germline mutation in a large Chinese pedigree with familial medullary thyroid carcinoma. | thyroid, |
| RET proto-oncogene germline mutation is associated with familial medullary thyroid carcinoma. | thyroid, |
| The relationship of cytomorphology of medullary thyroid carcinomas between family members with the same RET proto-oncogene mutation. | thyroid, |
| Specific expression of the ret proto-oncogene in human neuroblastoma cell lines. | neuroblastoma, |
| Mutation screening of RET proto-oncogene in a family with medullary thyroid carcinoma, marfanoid habitus and pheochromocytoma; from clinically MEN2B to genetically MEN2A syndrome.FAU - Hasani-Ranjbar, Shirin. | PCPG,thyroid, |
| RET, ROS1 and ALK fusions in lung cancer. | lung, |
| Bilateral adrenal pheochromocytoma with a germline L790F mutation in the RET oncogene. | PCPG,kidney, |
| Management of pheochromocytoma during pregnancy: laparoscopic adrenalectomy. | PCPG,kidney, |
| Hirschsprung disease of the colon, a vaginal mass and medullary thyroid cancer - a RET oncogene driven problem. | colorectal,thyroid, |
| Expression of the RET proto-oncogene is regulated by TFAP2C in breast cancer independent of the estrogen receptor. | breast, |
| Acute myeloid leukemia with translocation (8;16)(p11;p13) and MYST3-CREBBP rearrangement harbors a distinctive microRNA signature targeting RET proto-oncogene. | leukemia, |
| Medullary thyroid carcinoma (MTC) and RET proto-oncogene: mutation spectrum in the familial cases and a meta-analysis of studies on the sporadic form. | thyroid, |
| Data suggest that pheochromocytoma and paraganglioma can be divided into two groups based on mutations, cluster 1 (succinate dehydrogenases/von Hippel-Lindau syndrome protein) and cluster 2 (c-ret proto-oncogene/neurofibromin 1). [REVIEW] | PCPG,glioma, |
| Ponatinib (AP24534) is a novel potent inhibitor of oncogenic RET mutants associated with thyroid cancer. | thyroid, |
| RET codon 618 mutations in Saudi families with multiple endocrine neoplasia Type 2A and familial medullary thyroid carcinoma. | thyroid, |
| RET proto-oncogene mutations were found in a sample of 10 unrelated Saudi families with multiple endocrine neoplasia Type 2A and familial medullary thyroid carcinoma. The most frequent RET mutation was in codon 618 (exon 10). | thyroid, |
| [Clinical diagnosis and treatment of familial medullary thyroid carcinoma caused by a p.C618Y RET proto-oncogene mutation in a Chinese pedigree]. | thyroid, |
| These data establish mTOR as a key mediator of RET-mediated cell growth in thyroid cancer cells and provide a rationale for combinatorial treatments in thyroid cancers with oncogenic RET mutations. | thyroid, |
| Prophylactic thyroidectomy for MEN 2-related medullary thyroid carcinoma based on predictive testing for RET proto-oncogene mutation and basal serum calcitonin in China. | thyroid, |
| Effects of silencing the RET/PTC1 oncogene in papillary thyroid carcinoma by siRNA-squalene nanoparticles with and without fusogenic companion GALA-cholesterol. | thyroid, |